Idorsia Ltd

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Subsidiary

Employees: -

Market Cap: $464M

Website: http://www.idorsia.com

Clinical Trials

Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: ACT-389949 40 mg
Drug: ACT-389949 200 mg
Drug: ACT-389949 800 mg
Drug: ACT-389949 (Group C1 dose to be selected)
Drug: ACT-389949 (Group C2 dose to be selected)
Drug: Placebo

First Posted Date: 2014-03-28

Last Posted Date: 2018-07-10

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 65

Registration Number: NCT02099201

Locations: 🇬🇧
Celerion, Belfast, United Kingdom

Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206

Phase 1

Completed

Conditions: Safety
Tolerability
Pharmacodynamics
Pharmacokinetics

Interventions: Drug: ACT-462206 5 mg
Drug: ACT-462206 25 mg
Drug: ACT-462206 100mg
Drug: ACT-462206 200mg
Drug: ACT-462206 1500mg
Drug: ACT-462206 400mg
Drug: ACT-462206 1000 mg
Drug: Placebo
Drug: Almorexant 400mg

First Posted Date: 2013-10-07

Last Posted Date: 2018-07-10

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 56

Registration Number: NCT01954589

Locations: 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands

Single-ascending Oral Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-281959 / ACT-246475 in Healthy Male Subjects

Phase 1

Completed

Conditions: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics

Interventions: Drug: ACT-281959 prodrug formulation I (Groups C to G doses to be defined)
Drug: 5 mg ACT-281959 prodrug formulation I (Group A)
Drug: 20 mg ACT-281959 prodrug formulation I (Group B)
Drug: Placebo (Groups A to F)
Drug: ACT-281959 prodrug formulation II (Group G dose to be defined)
Drug: ACT-246475 (Group G dose to be defined)

First Posted Date: 2013-10-07

Last Posted Date: 2018-07-10

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 49

Registration Number: NCT01954615

Locations: 🇫🇷
Biotrial, Rennes, France

Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: ACT-129968 500 mg tablet
Drug: ACT-129968 250 mg capsule

First Posted Date: 2013-06-14

Last Posted Date: 2018-07-10

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 20

Registration Number: NCT01877629

Locations: 🇩🇪
PHAROS GmbH Clinical Research, Ulm, Germany

Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis

Phase 3

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: Placebo
Drug: ACT-129968
Drug: Cetirizine

First Posted Date: 2011-12-02

Last Posted Date: 2018-09-28

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 630

Registration Number: NCT01484119

Locations: 🇺🇸
Clinical Investigative Site 7903, New Braunfels, Texas, United States
🇺🇸
Clinical Investigative Site 7905, Austin, Texas, United States
🇺🇸
Clinical Investigative Site 7901, San Antonio, Texas, United States

and more 4 locations

Essential Hypertension

Phase 2

Completed

Conditions: Essential Hypertension

Interventions: Drug: ACT-280778
Drug: Placebo
Drug: Amlodipine

First Posted Date: 2010-12-22

Last Posted Date: 2018-09-27

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 196

Registration Number: NCT01264692

Locations: 🇷🇸
Clinical Investigative Site 3001, Belgrade, Serbia
🇷🇸
Clinical Investigative Site 3004, Belgrade, Serbia
🇷🇸
Clinical Investigative Site 3000, Niska Banja, Serbia

and more 15 locations

Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis

Phase 2

Completed

Conditions: Seasonal Allergic Rhinitis

Interventions: Drug: ACT-129968
Drug: Cetirizine
Drug: Placebo

First Posted Date: 2010-11-16

Last Posted Date: 2019-05-15

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 579

Registration Number: NCT01241214

Locations: 🇺🇸
Clinical Investigative Site 7902, San Antonio, Texas, United States
🇺🇸
Clinical Investigative Site 7901, San Antonio, Texas, United States
🇺🇸
Clinical Investigative Site 7906, San Antonio, Texas, United States

and more 4 locations

Clinical Study to Explore the Efficacy of ACT-129968 in Patients With Partly Controlled Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Setipiprant
Drug: Placebo

First Posted Date: 2010-10-21

Last Posted Date: 2018-07-09

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 438

Registration Number: NCT01225315

Locations: 🇵🇱
Clinical Investigative Site # 5501, Lodz, Poland
🇺🇸
Clinical Investigative Site # 6215, New Orleans, Louisiana, United States
🇺🇸
Clinical Investigative Site 6202, Knoxville, Tennessee, United States

and more 94 locations

Tezosentan in Patients With Pulmonary Arterial Hypertension

Phase 2

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: ACT-050089
Other: Placebo

First Posted Date: 2010-03-26

Last Posted Date: 2018-07-09

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 2

Registration Number: NCT01094067

Locations: 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇯🇵
National Cardiovascular Center, Osaka, Japan
🇫🇷
Hopital Antoine Beclere, Clamart, France

and more 2 locations

Tezosentan in Pulmonary Arterial Hypertension

Phase 2

Terminated

Conditions: Pulmonary Arterial Hypertension

Interventions: Drug: Tezosentan

First Posted Date: 2010-03-01

Last Posted Date: 2018-07-09

Lead Sponsor: Idorsia Pharmaceuticals Ltd.

Target Recruit Count: 3

Registration Number: NCT01077297

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇫🇷
Hopital Antoine Béclère, Paris, Clamart, France

and more 2 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy